Ulcerative colitis disease severity affects the speed of symptom relief under filgotinib treatment: a analysis of the phase 2b/3 SELECTION study

Background/Aims Filgotinib is an oral, once-daily, Janus kinase 1 preferential inhibitor approved for the treatment of ulcerative colitis (UC). This study aimed to assess symptomatic response with filgotinib 200 mg (FIL200) according to disease severity using baseline partial Mayo Clinic Score (pMCS...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Masayuki Saruta, Silvio Danese, Yoshie Takatori, Toshihiko Kaise, Christine Rudolph, Marc Ferrante, Toshifumi Hibi
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Korean Association for the Study of Intestinal Diseases 2026-04-01
Rangatū:	Intestinal Research
Ngā marau:	inflammatory bowel disease janus kinase inhibitors ulcerative colitis
Urunga tuihono:	http://irjournal.org/upload/pdf/ir-2024-00169.pdf
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!